276 related articles for article (PubMed ID: 21488592)
21. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.
Blode H; Klipping C; Richard F; Trummer D; Rohde B; Diefenbach K
Contraception; 2012 Feb; 85(2):177-84. PubMed ID: 22067789
[TBL] [Abstract][Full Text] [Related]
22. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
[TBL] [Abstract][Full Text] [Related]
23. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
24. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
[TBL] [Abstract][Full Text] [Related]
27. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of a new oral contraceptive containing drospirenone.
Shulman LP
J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
[TBL] [Abstract][Full Text] [Related]
29. Estradiol + nomegestrol. Oral contraceptive claimed to be more natural, but presenting no obvious advantages.
Prescrire Int; 2012 Dec; 21(133):292. PubMed ID: 23373095
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Dinger J; Bardenheuer K; Heinemann K
Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
[TBL] [Abstract][Full Text] [Related]
31. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Gaspard U; Scheen A; Endrikat J; Buicu C; Lefebvre P; Gerlinger C; Heithecker R
Contraception; 2003 Jun; 67(6):423-9. PubMed ID: 12814810
[TBL] [Abstract][Full Text] [Related]
32. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
33. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
[TBL] [Abstract][Full Text] [Related]
34. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Jick SS; Hernandez RK
BMJ; 2011 Apr; 342():d2151. PubMed ID: 21511805
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
[TBL] [Abstract][Full Text] [Related]
36. Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old.
De Groote D; Perrier d'Hauterive S; Pintiaux A; Balteau B; Gerday C; Claesen J; Foidart JM
Contraception; 2009 Aug; 80(2):187-93. PubMed ID: 19631796
[TBL] [Abstract][Full Text] [Related]
37. [Venous thromboembolism in adolescents associated with fourth-generation oral contraceptives].
Botzenhardt S; Toni I; Rascher W; Neubert A
Klin Padiatr; 2013 Sep; 225(5):268-76. PubMed ID: 23979828
[TBL] [Abstract][Full Text] [Related]
38. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
39. Thrombotic risk of contraceptive transdermal patches and the contraceptive vaginal ring.
Prescrire Int; 2013 Nov; 22(143):266, 268-9. PubMed ID: 24427838
[TBL] [Abstract][Full Text] [Related]
40. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
